Skip to main content

Capecitabine Disease Interactions

There are 6 disease interactions with capecitabine:

Major

Antineoplastics (applies to capecitabine) infections

Major Potential Hazard, High plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Fludara (fludarabine)." Berlex, Richmond, CA.
  2. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company, Indianapolis, IN.
  3. "Product Information. Doxil (doxorubicin liposomal)." Sequis Pharmaceuticals Inc, Menlo Park, CA.
  4. "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb, Princeton, NJ.
  5. "Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.
  6. "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.
  7. "Product Information. Novantrone (mitoxantrone)." Immunex Corporation, Seattle, WA.
  8. Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992): 314-5
  9. "Product Information. Tabloid (thioguanine)." Prasco Laboratories, Cincinnati, OH.
  10. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  11. "Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.
  12. "Product Information. Platinol (cisplatin)." Bristol-Myers Squibb, Princeton, NJ.
  13. "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  14. Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990): 833-4
  15. "Product Information. Alkeran Tablets (melphalan)." Glaxo Wellcome, Research Triangle Pk, NC.
  16. "Product Information. Hycamtin (topotecan)." SmithKline Beecham, Philadelphia, PA.
  17. "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn, Kalamazoo, MI.
  18. "Product Information. Nipent (pentostatin)." Hospira Inc, Lake Forest, IL.
  19. Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991): 671
  20. "Product Information. DTIC-Dome (dacarbazine)." Bayer, West Haven, CT.
  21. Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994): 407-8
  22. "Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation), Eatontown, NJ.
  23. "Product Information. Vepesid (etoposide)." Bristol-Myers Squibb, Princeton, NJ.
  24. "Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation, Eatontown, NJ.
  25. Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992): 1396-7
  26. "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.
  27. "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb, Princeton, NJ.
  28. "Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome, Research Triangle Pk, NC.
  29. "Product Information. Methotrexate (methotrexate)." Lederle Laboratories, Wayne, NJ.
  30. "Product Information. Xeloda (capecitabine)." Roche Laboratories, Nutley, NJ.
  31. "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb, Princeton, NJ.
View all 31 references
Major

Capecitabine (applies to capecitabine) coronary artery disease

Major Potential Hazard, Moderate plausibility. Applicable conditions: Ischemic Heart Disease

Capecitabine can cause cardiotoxicity including myocardial infarction, ischemia, angina, dysrhythmias, cardiac failure, sudden death, electrocardiographic changes and cardiomyopathy. These adverse reactions can be more common in patients with a prior history of coronary artery disease.

Major

Capecitabine (applies to capecitabine) myelosuppression

Major Potential Hazard, Moderate plausibility. Applicable conditions: Fever, Bleeding, Bone Marrow Depression/Low Blood Counts

Capecitabine is metabolized by the liver to fluorouracil (5-FU). Fluorouracil induces bone marrow suppression. Leukopenia, thrombocytopenia, and anemia, some severe, have been reported with capecitabine therapy. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitoring of hematopoietic function is recommended

References

  1. "Product Information. Xeloda (capecitabine)." Roche Laboratories, Nutley, NJ.
Major

Capecitabine (applies to capecitabine) renal dysfunction

Major Potential Hazard, Moderate plausibility.

Capecitabine is contraindicated in patients with severe renal impairment (creatinine clearance below 30 mL/min). Patients with moderate renal impairment at baseline require a dose reduction. Patients with mild and moderate impairment should be carefully monitored for adverse reactions and prompt interruption of therapy with subsequent dose adjustment might be required depending on the developed adverse events.

Moderate

Capecitabine (applies to capecitabine) dehydration

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diarrhea, Vomiting

Dehydration has been observed in patients receiving capecitabine and it may cause acute renal failure which could be fatal. Patients with asthenia, anorexia, nausea, vomiting or diarrhea may rapidly become dehydrated. Patients should be monitored to prevent and correct dehydration at the onset. If dehydration grade 2 or higher occurs, treatment should be interrupted until dehydration is corrected. Since capecitabine can also induce diarrhea, sometimes severe, patients should be carefully monitored and receive fluid and electrolyte replacement. Standard antidiarrheal treatments are recommended.

Moderate

Capecitabine (applies to capecitabine) hepatic dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Capecitabine is extensively metabolized by the liver. In patients with mild to moderate liver dysfunction due to liver metastases the Cmax and AUC of capecitabine were increased 60%. These patients should be carefully monitored when capecitabine is administered. The effect of severe hepatic dysfunction on capecitabine has not been assessed. Clinical monitoring of hepatic function is recommended for patients with compromised hepatic function.

References

  1. "Product Information. Xeloda (capecitabine)." Roche Laboratories, Nutley, NJ.

Capecitabine drug interactions

There are 220 drug interactions with capecitabine

Capecitabine alcohol/food interactions

There is 1 alcohol/food interaction with capecitabine

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.